GLPwatch
Papers (12034)
Page 195 of 201, ranked by citation count.
- Weight "regain" in obesity shifts responsibility from biology to personal inadequacy.
- Comparison of Pediatric and Adult Glucagon-Like Peptide-1 Receptor Agonist Exposures Reported To United States Poison Centers, 2017-2024.
- Semaglutid: Ein wirksames Medikament zur Gewichtsabnahme.
- Liraglutide in Prader Willi-Syndrome: The Importance of Placebo-Controlled Studies.
- Correction to "Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3".
- Correction: Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial.
- Achieving BMI <25 kg/m<sup>2</sup> was associated with reduced predicted risk of atherosclerotic cardiovascular disease in people with obesity or overweight on tirzepatide or placebo: a post hoc analysis of SURMOUNT-1, -3, and -CN.
- Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions.
- The evidence for oral semaglutide in type 2 diabetes from a managed care perspective.
- Comparative effects of lifestyle modification, metformin and exenatide/glargine combination therapy on daily glycaemic fluctuation in the setting of near-normoglycaemia.
- A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
- Tirzepatide during Ramadan in people with obesity without diabetes: A critical knowledge gap.
- GLP-1 receptor agonist suppresses fatty infiltration while improving range of motion and electromyographic function in a chronic rotator cuff tear rat model.
- Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction.
- In brief: Rybelsus R2 rebranded as Ozempic.
- Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. Reply.
- Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.
- Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category.
- Interpreting Lean Mass Changes During Tirzepatide-Induced Weight Loss: Beyond Quantitative Metrics.
- In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.
- Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis.
- Association Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis.
- Personalized Combination of a Ketogenic Diet and Low-Dose Semaglutide for Cardiometabolic Health: A Retrospective Case Series.
- Papillary thyroid carcinoma discovered in a patient on semaglutide therapy for metabolic syndrome: a case presentation and review of current evidence.
- Tirzepatide: A turning point in obesity related heart failure with preserved ejection fraction?
- Marked improvement in severe hidradenitis suppurativa following tirzepatide therapy: a case report.
- South African Hypertension Society 2012 congress report.
- Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Ozempic and dental therapy.
- Tirzepatide and Metformin Effects on Hunger and BMI in an Adolescent with Hyperphagia and Severe Obesity due to MC4R Deficiency: A Case Report.
- Correction: Metabolic resilience: liraglutide's potential in alleviating depressive symptoms.
- Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss.
- GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways.
- Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia.
- Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
- Advances in proteomics research related to semaglutide: evidence from humans and animals.
- Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement.
- Acute Deep Vein Thrombosis in the Setting of Tirzepatide Use: A Case Highlighting Emerging Concerns.
- Exploring Weight Loss Medication Discourse: Mixed Methods Analysis of US-Based Facebook Posts.
- Chronic Liraglutide Administration Fails to Suppress Postprandial Glucagon Levels in Type 1 Diabetic Islet Allograft Recipients With Graft Dysfunction.
- Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort.
- Semaglutide Inhibits Neuronal Apoptosis and Improves Cognitive Function in Mice after Traumatic Brain Injury, Mainly via the Caspase-Dependent Pathway.
- Severe Adverse Effects of Tirzepatide Overdose Requiring Intensive Care Unit Admission and Complex Rehabilitation.
- Understanding Biased Signaling and Small-Molecule Binding for Treatment of Type 2 Diabetes Mellitus and Obesity at the Glucagon-Like Peptide-1 Receptor (GLP-1R) Based on Molecular Dynamics Simulations.
- What impact could tirzepatide have on major cardiovascular complications in patients with obstructive sleep apnea?
- In Silico Exploration of Therapeutics for GLP-1 Receptor Agonist-Induced Nausea and Their in Vivo Validation in Mice.
- D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice.
- Semaglutide Protects Retinal Ganglion Cells Against Rotenone-Induced Degeneration via Improved Glucose Metabolism.
- Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study.
- Retatrutide in type 2 diabetes mellitus and obesity: an overview.
- Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid Blepharoplasty.
- Effect of combined administration of Acyl-CoA: Cholesterol acyltransferase 1 inhibitor and glucagon-like peptide 1 receptor agonist on a rodent model of diet-induced obesity.
- Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study.
- Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS.
- GLP1R Agonists and Precision Medicine: In Search of Predictive Biomarkers.
- Challenges in the management of obesity.
- Semaglutide as a potential therapeutic adjunct for reducing flare-ups in Sjögren's syndrome: A case report.
- Not Just Skin Deep: A Hidden Complication of Tirzepatide Therapy.
- Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.